Alpha 2.0
Login Register
» Articles » PMID: 32579717

The Investigation and Management of Follicular Lymphoma

Overview
Journal Br J Haematol
Specialty Hematology
Date 2020 Jun 25
PMID 32579717
Citations 5
Authors
Christopher McNamara
Silvia Montoto
Toby A Eyre
Kirit Ardeshna
Cathy Burton
Tim Illidge
Kim Linton
Simon Rule
William Townsend
Wai L Wong
Pam McKay
Affiliations
Soon will be listed here.
Citing Articles

Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review.

Wang C, Dong Y, Men P, Zhang R, Xiao Y, Bu Y Front Pharmacol. 2025; 15():1426772.

PMID: 39830356 PMC: 11738910. DOI: 10.3389/fphar.2024.1426772.

Unraveling the complexity of follicular lymphoma: insights and innovations.

Li X, Li N, Liu Y, An L Am J Cancer Res. 2025; 14(12):5573-5597.

PMID: 39803651 PMC: 11711519. DOI: 10.62347/MFUG2190.

Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations.

Varon B, Horowitz N, Khatib H Patient Prefer Adherence. 2024; 18:2159-2167.

PMID: 39479221 PMC: 11523922. DOI: 10.2147/PPA.S485838.

Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.

Berger T, Shochat T, Aumann S, Nachmias B, Goldschmidt N, Horesh N Ann Hematol. 2023; 102(8):2127-2136.

PMID: 37335322 DOI: 10.1007/s00277-023-05306-2.

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study.

Trotman J, Presgrave P, Carradice D, Lenton D, Gandhi M, Cochrane T Hemasphere. 2023; 7(3):e836.

PMID: 36844180 PMC: 9946407. DOI: 10.1097/HS9.0000000000000836.